Clinical Study
CAP-1002: A Study Drug for Human Allogeneic Cardioshere-Derived Cells for People with Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) is a disease that weakens people's muscles over time. CAP-1002 is a study drug to help people with this disease. Research is needed to learn the safety and effectiveness of the drug. This information we gain may aid future patients.
For more information contact:
Sarah Moldt
sarah.moldt@hsc.utah.edu
801-585-9399
IRB#: IRB_00150933
| PI: Russell Butterfield
| Department: PEDIATRIC NEUROLOGY
| Approval Date: 2022-09-15 06:00:00
Study Categories: Neurological Studies
| Specialties: Neurology
Who can participate?
Gender: Male Only
Age: Over 7 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 10 years and older
- Duchenne Muscular Dystrophy (DMD) diagnosis
- Taking medication such as prednisone for at least 12 months, and must have stable health for at least 6 months
- Receiving care at a credible multidisciplinary DMD center
- In-person at the University of Utah
Exclusion Criteria:
- Already received other specific treatments at 3, 6, or 12 months
- History or current drug or alcohol abuse
- Use metformin or insulin within 3 months before participation
- Severe illness 30 days before participation
- Planned surgery 6 months during participation
Will I be paid for my time?
Yes